1. Scrip
  2. >>R&D
  3. >>Clinical Trials

RAINFALLs On Lilly's Cyramza Stomach Cancer Parade

 
• By Alexandra Shimmings

A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.

Raindrops
Rainy days for Lilly's Cyramza plans • Source: Shutterstock

Eli Lilly & Co.'s VEGF inhibitor Cyramza (ramucirumab) has failed to improve overall survival when used first line in stomach cancer, top-line data from the RAINFALL study show. The company has dropped plans to file for a supplemental approval in what could have been a lucrative expanded indication where there is limited competition.

Lilly said that while the 645-patient study met its primary endpoint of progression-free survival, it did not provide a benefit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.